After winning the DoD EHR Modernization contract with Cerner, Leidos has been awarded a prime contract by the U.S. Army to provide medical product and research development to the U.S. Army Medical Research and Materiel Command (USAMRMC). The USAMRMC develops, acquires, provides, and sustains world-class solutions and capabilities to enable medical readiness globally.The multiple-award indefinite-delivery/indefinite-quantity contract has a five-year base period of performance, five-one year options worth a total value of $900 million for all awardees, if all options are exercised. Leidos is one of four contractors eligible to compete for task orders under the contract.
Under the contract, Leidos Life Sciences will provide medical product research and development services to support the missions of the U.S. Army Medical Materiel Development Activity, U.S. Army Medical Materiel Agency, other subordinate commands of the U.S. Army Medical Research and Materiel Command, Joint Project Manager Medical Countermeasure Systems, and other Department of Defense (DoD) entities responsible for medical product research and development. Work under the contract is intended to support the entire scope of developing new drugs, vaccines, blood products, medical devices, and medical support equipment that enhances readiness, ensures the provision of the highest quality medical and preventive care to the DoD, and maximizes survival of medical casualties on the battlefield.
“Our Life Sciences team located in Frederick, Maryland, led by Dr. Jim Pannucci, has proudly supported the U.S. Army Medical Research and Material Command for more than 33 years,” said Jerry Hogge, deputy group president of Leidos Federal Health in an official statement. “Our distinguished scientists and researchers look forward to providing research and development for medical products to deliver solutions that can help save and improve the lives of our military service members.”
Work will be performed primarily in Frederick, Md.